Stroke Special Report Trials of Trials in Acute Ischemic Stroke
The Humana Lecture Harold P. Adams, Jr, MD Afew years ago, a distinguished colleague and expert in stroke told me, "When we have a treatment for stroke, we will know it" (R. Siekert, personal communication). I agree with this insightful comment, but I also wonder how we will know.
Because stroke is a very complex condition with a number of clinical variables that compound care and influence outcome, it is unlikely that any therapy will produce such a dramatic response that the medical community will accept the benefit of any treatment based only on anecdotal, uncontrolled reports. Thus, a carefully organized experimental and clinical research program is needed to adequately examine any promising therapy for ischemic stroke.1~3 During the last three decades, a number of studies have examined the possible usefulness of treatments for stroke, but their results are inconclusive. Unfortunately, some of these studies suffered from problems in design that may, in part, partially explain the negative results.?2 Having been actively involved in the development of several clinical research studies in stroke and having made more than my fair share of mistakes, I wish to share some ideas that might help all of us in our future research endeavors. Some recommendations may be controversial, but they might serve as a springboard for future discussion. These comments supplement previous suggestions. 1, 3 The goal should be to avoid problems in design and conduct that would hamper the trial's ability to adequately test the intervention.
Recently, Wardlaw and While a randomized clinical trial is the only definitive way to test any intervention for acute ischemic stroke, such an expensive project should not be launched unless there is strong evidence from experimental and pilot clinical studies that there is a reasonable chance for success. The therapy to be tested should make biologic sense. Data from experimental studies should be unequivocally positive. The pharmacological and pharmocodynamic properties of any drug should be known; the most promising treatments will be those that have an immediate effect. Future trials that examine any therapy aimed at reversing the acute ischemic process will not have the luxury of testing a drug or regimen that may not act for 24 to 48 hours. For example, the lag of up to 48 hours after treatment initiation before the desired reductions in hematocrit were achieved may explain the failure of hypervolemic hemodilution therapy to improve outcomes of patients with acute ischemic stroke.
For an intervention to have widespread clinical applicability, it must be easy to administer and monitor. For example, although intra-arterial infusions of thrombolytic drugs might be useful, it is likely that such treatment will be available to only a limited number of persons with stroke. What is needed is a practical and easy route of administration that can be used by physicians in an emergency room or by emergency medical personnel. A drug that requires a complex regimen, invasive route of administration, sophisticated and special monitoring equipment, or intensive ancillary care will have limited acceptance. Any drug that might be successful in care needs a clear and acceptable margin of safety. A drug that is accompanied by a high risk for major or life-threatening complications such as anaphylaxis, hypotension, serious cardiac arrhythmias, seizures, coma, psychosis, brain edema, or intracranial bleeding may not be widely used by physicians even if it is effective. Such a drug may be efficacious, but it will not be useful.
Issues of safety and possible efficacy are best addressed by pilot clinical studies. They are a critical first step in providing information to justify a large randomized trial. Even though a drug may be safe in healthy young volunteers, its safety profile may differ in a population of elderly, acutely ill persons with stroke.
The primary emphasis of a pilot study is determination of the frequency and severity of adverse experiences that can be attributed to the drug. The type and severity of observed side effects also facilitate refinement of inclusion and exclusion criteria to be used in the subsequent randomized trial. For example, two hemorrhagic events in the pilot studies of Org 10172 led to changes in two exclusion criteria. 6 The upper limit for an acceptable blood pressure was lowered from 140 mm Hg to 130 mm Hg, and patients who had evidence of shift of midline structures on a baseline CT examination were excluded.
Pilot studies can also determine the best regimen, dosage, and duration of therapy. One aim should be to achieve desired therapeutic effects of the drug as rapidly as possible. Thus, issues such as the need for a loading dose and maintenance treatment can be resolved in the pilot study. Establishing the optimal dose is often difficult, as attested by the recent controversies about the ideal dose of aspirin or warfarin to prevent stroke.7-'0 Still, a pilot study should determine the dose to be used in the randomized trial. The usual paradigm is a dose-escalation regimen with increasing doses tested among subsequently enrolled patients as safety is demonstrated at lower doses. When side effects begin to occur at an unacceptable rate, the dose is assumed to be too high. The intent is to achieve a dose sufficiently high to ensure that the drug will not miss any dose-related benefit but not so high that dose-related adverse experiences occur at an unacceptable rate. Thus, the "optimal" dose that is selected to be tested in a randomized trial is the largest dose not associated with high rates of adverse effects.
Some pilot studies enroll persons who do not receive active therapy. Such a design avoids comparison with historical controls and also allows monitoring of the vehicle (placebo) for side effects. Thus, a pilot controlled study might give a hint about efficacy. However, most pilot studies are small (fewer than 100 patients), and any differences must be dramatic to provide a trend for efficacy. Conversely, weaknesses are inherent in a controlled pilot study. Actual experience with the active drug is less because a sizeable portion of the patients do not receive treatment. This increases the likelihood of missing uncommon but potentially important side effects. In addition, because of the small size, any data on efficacy may be misleading. Because of the vulnerability of a small controlled trial to the incongruities in patient populations, the data may be falsely positive or negative. In particular, a small pilot study can lead to the conclusion that an intervention is not effective, a scenario that has occurred too frequently. In addition, a small, controlled dose-escalation study, in which very few persons are treated at each level, is susceptible to misleading information about a dose relationship to efficacy. Before investigators commence a small, controlled pilot study, they should review the many pitfalls of this approach. In particular, the data should not be used to determine efficacy or lack of efficacy of the treatment.
K.I.S.S. Entering all patients with stroke, regardless of etiology, best replicates care that patients will likely receive in an emergency room. In addition, categorization of subtypes of ischemic stroke is difficult because clinical features often overlap and imaging is nonspecific.13,14 Excluding a subtype necessitates extensive baseline studies, which will postpone treatment; even when the results of several diagnostic studies are known, physicians often disagree about the most likely etiology.14 As a result, misrandomizations will take place despite the best efforts of the investigators; ineligible patients will inadvertently be entered and eligible patients will be excluded. Overall, the complexity of the trial will be unnecessarily increased and recruitment will be critically hampered because of the uncertainties in subtype diagnosis.
Another problem for investigators is the selection of interventions that can be allowed in conjunction with the study drug. Ancillary care should be as uniform as possible so that differences in outcomes can be attributed to the agent being tested. Provisions for supportive care, rehabilitation, and control of complications should be included in the protocol. Poststroke rehabilitation should be encouraged. Data about auxiliary measures prescribed during the acute treatment and follow-up phases of the study should be recorded. Several medical or surgical measures (aspirin, ticlopidine, warfarin, carotid endarterectomy) are of proven usefulness in preventing stroke among high-risk patients.7 [15] [16] [17] [18] [19] in a trial of an antithrombotic drug, such as a low molecular weight heparinoid, may be more worried about the hemorrhagic transformation of an infarction detected by CT in a patient who is receiving the active drug than in a patient who is known to be receiving the control. In such circumstances, the drug may be prematurely and unnecessarily discontinued. There is no way that an independent rater blinded to the trial protocol can compensate for such judgments.
There are several well-described ways to assure blinding of treating personnel. If a parenteral drug is given, a similar appearing placebo likewise can be administered. The same guidelines can be applied to a trial of an oral therapy. To promote patient safety, some drugs will require monitoring levels of the drug or of a biologic response, such as a partial thromboplastin time in a patient receiving heparin. In such circumstances, a trial can enlist a local unblinded "safety" physician, who is otherwise not involved in the care of enrolled patients, to receive the results of any monitoring tests and to recommend adjustments in doses of active therapy. To avoid clues to treatment allocation, the trial would also provide the safety physician with a schedule of "dose adjustments" in randomly selected patients in the control group. This methodology was successfully used in one of the recently completed trials of oral anticoagulants in patients with atrial fibrillation,24 and it greatly strengthened the trial's conclusions. The time, expense, and hassle of conducting a truly blinded clinical trial will ultimately pay great dividends in increased credibility. The ongoing Trial of Org 10172 in Acute Stroke Treatment (TOAST) has adapted the methodology described by Ezekowitz et a124 to its study of the low molecular weight heparinoid in stroke.
Stroke Scales Clinical recovery is the primary way to ascertain a response to treatment; the real goal of patient care is improving the rate of favorable outcomes. Measuring treatment effects using criteria such as differences in the size of brain lesions on CT or the rates of recanalization of arteries are not as medically significant as dissimilarities in obvious responses such as disability or neurological impairment. Physicians and the public primarily want to know whether the drug reduces mortality and improves the quality of life among survivors. This should be the goal of any trial. Because patients spontaneously recover after stroke, any early improvement in the patients' neurological condition should be sustained and followed by a high rate of favorable outcomes. A short-term dramatic response that is not maintained is not the final measure of efficacy. Assessments should be extended beyond the acute treatment period to permit measurement of any delayed complications of the stroke or treatment. A follow-up examination at 3 to 6 months allows for the effects of the natural recovery after stroke to be incorporated, and this assessment should be the primary outcome determination. For results of the trial to be accurate, this follow-up examination should be performed in all subjects.
Investigators should overcome the inclination to develop a new stroke scale. There are already too many scales, and it is unlikely that any new scale will be significantly better than those already in existence. There are only so many ways to quantify the neurological impairments in persons with stroke. Creating and validating a stroke scale is a time-consuming endeavor that impedes the actual performance of the trial. Because trials involve examinations of patients at several centers, researchers should use scales that are valid and reliable and have good levels of interrater agreement. Any stroke outcome scale should also be immune to influences of gender, age, culture, language, geography, education, social class, or occupation. A good scale is one that is unambiguous and easy to use.
The best scales detect clinically important differences and avoid inflation of minimal changes that are of dubious significance. For example, a two-point difference between groups based on a 100-point scale might be statistically significant and clinically meaningless. The simple categorization of outcomes recommended by van Researchers should expect that the time required to actually start the trial will be longer than estimated. The actual time to finalize the protocol; to complete negotiations with participating institutions, regulators, and the pharmaceutical company; and to resolve issues with institutional review boards will be approximately three times that originally predicted. The whole process, which also includes finalizing budgets, obtaining letters of indemnification, and certifying investigators and laboratories, is extraordinarily obtuse. Investigators should persevere because this byzantine administrative process will become more streamlined as the trial progresses.
Conclusions
Any clinical trial is a trial. It is not only a trial of the intervention being tested, it is a trial of the scientific method being applied to the art and inexact science of patient care. It is also a trial of the investigators' ability to design and operate a large clinical research program. In addition, it is a trial of everyone's stamina, patience, and goodwill.
Yet, these are exciting times for clinical research in stroke. A number of promising therapies are being tested, and it is likely that one or more of them will be demonstrated as useful. We should learn from past mistakes and build on past and future successes. Even if the results of a well-designed trial are negative, such a study is important. It may halt research on a treatment that truly is ineffective, and resources can then be directed toward testing other interventions. A welldesigned trial also serves as the foundation for future clinical research. Testing exciting and promising treatments through the use of modern clinical trial methods should allow us to soon state, "We have a treatment for acute ischemic stroke and we know it."
